Perspective Therapeutics, Inc. (CATX) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-03-04

Key Insights

Heidi Henson, a director of Perspective Therapeutics, Inc. (CATX), has been granted 50,000 stock options with a strike price of $5.35 and a vesting date of March 2, 2027, as part of her annual equity award.
The option grant was approved by the company's Board of Directors on January 26, 2026, indicating the company is providing long-term incentives to its directors.
The insider transaction represents a direct ownership of 50,000 shares, which could signal Henson's confidence in the company's future prospects.

Want the newest filings?

This analysis covers the filing from 2026-03-04. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-03-04

The reporting person, Maria E. Martinez, has been granted a stock option to acquire 50,000 shares of the issuer's common stock, vesting in full on March 2, 2027.
This appears to be an annual equity award for Ms. Martinez's role as a director of the issuer, Perspective Therapeutics, Inc.
The option has an exercise price of $5.35 per share, which may provide an opportunity for Ms. Martinez to benefit from potential share price appreciation in the future.

Filed: 2026-03-04

The filing indicates that Frank Morich, a director of Perspective Therapeutics, Inc. (CATX), has been granted a stock option to acquire 50,000 shares of the company's common stock.
The stock option has an exercise price of $5.35 per share and a 10-year term, vesting fully on March 2, 2027, subject to Morich's continued service on the board.
This stock option award appears to be Morich's annual equity compensation for 2026, as approved by the company's board of directors on January 26, 2026.

Filed: 2026-03-04

Robert F. Williamson, III, a director of Perspective Therapeutics, Inc. (CATX), has been granted a stock option to purchase 50,000 shares of the company's common stock at $5.35 per share.
The option grant was approved by the company's Board of Directors on January 26, 2026, with a vesting date of March 2, 2027, subject to Williamson's continued service on the vesting date.
Insider transactions, such as this option grant, can provide insights into management's confidence in the company's future performance and align their interests with shareholders.

Filed: 2026-03-04

Lori A. Woods, a director of Perspective Therapeutics, Inc., has been granted 50,000 stock options with an exercise price of $5.35 and a 10-year expiration date.
The stock option grant was approved by the company's Board of Directors on January 26, 2026, and the grant date is March 2, 2026, suggesting this is part of the director's annual equity compensation.
The stock options vest in full on March 2, 2027, subject to the director's continued service on the vesting date, indicating this is a standard time-based vesting schedule.

Filed: 2026-03-04

The reporting person, Johan M. Spoor, who is the Chief Executive Officer and a Director of Perspective Therapeutics, Inc., has been granted a stock option for 735,000 shares of the company's common stock. This indicates the company is incentivizing its top executive with a significant equity award, potentially aligning his interests with shareholders.
The stock option has a 10-year term and vests over four years, suggesting a long-term focus on the company's growth and performance.
The exercise price of the option is $5.35, which could provide the reporting person with an opportunity to profit if the company's stock price increases over time.

Filed: 2026-03-04

Jonathan Hunt, the Chief Accounting Officer, has been granted a stock option of 90,000 shares of the company's common stock, vesting over 4 years. This indicates the company's commitment to incentivize and retain key management.
The stock option has an exercise price of $5.35, which is the current market price, suggesting the grant is intended to align management's interests with shareholders.
The timing of the grant, in early March 2026, may signal the company's confidence in its near-term outlook and a desire to reward and motivate its accounting leadership.

Filed: 2026-03-04

Markus Puhlmann, the Chief Medical Officer of Perspective Therapeutics, Inc. (CATX), was granted a stock option to acquire 150,000 shares of the company's common stock, indicating management's confidence in the company's future prospects.
The option has a 10-year term and vests over 4 years in equal monthly installments, aligning Puhlmann's interests with those of long-term shareholders.
The exercise price of $5.35 per share represents a premium to the current market price, suggesting the board believes the stock is undervalued and has potential for future growth.

Other reports for Perspective Therapeutics, Inc.

Quarterly Report Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.